NCT02697838 is a Phase 2 clinical trial of Apatinib in Malignant Neoplasm of Stomach Stage II, sponsored by Fujian Cancer Hospital.

Who is sponsoring NCT02697838?

NCT02697838 is sponsored by Fujian Cancer Hospital.

What drugs are being tested in NCT02697838?

Interventions in NCT02697838: Apatinib, Paclitaxel-based chemotherapeutic regimens.

What condition does NCT02697838 study?

NCT02697838 studies Malignant Neoplasm of Stomach Stage II.

Is NCT02697838 still recruiting?

NCT02697838 is currently status unknown. Last updated 17 October 2018.

Last reviewed 2018-10-17 · How we verify

NCT02697838

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

Status unknown Phase 2 Last updated 17 October 2018

What this trial tests

Phase 2 trial testing Apatinib in Malignant Neoplasm of Stomach Stage II in 20 participants. Status unknown.

Timeline

1 August 2016

Primary endpoint
31 March 2018

31 October 2018

Quick facts

Lead sponsor	Fujian Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 August 2016
Primary completion	31 March 2018
Estimated completion	31 October 2018
Sites	1 location across China

Drugs / interventions tested

Apatinib (Apatinib) — full drug profile →
Paclitaxel-based chemotherapeutic regimens — full drug profile →

Conditions studied

Malignant Neoplasm of Stomach Stage II — all drugs for Malignant Neoplasm of Stomach Stage II →

Sponsor

Fujian Cancer Hospital

Who can join

18 and older, any sex, with Malignant Neoplasm of Stomach Stage II. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A single arm study: Apatinib plus paclitaxel as the reverses treatment in advanced gastric cancer which paclitaxel-resistant.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells.
Bergonzini C, Gregori A, Hagens TMS, van der Noord VE, et al · · 2024 · cited 24× · PMID 38163893 · DOI 10.1186/s13046-023-02879-8
Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study.
Zhao S, Fan N, Li H, Liu J, et al · · 2020 · cited 8× · PMID 33178765 · DOI 10.21037/atm-20-5841

Verify or expand the search:

Other trials of Apatinib

Trials testing the same drug.

NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07031154 — A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Rese · Phase 2 · not yet recruiting
NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting

Other Fujian Cancer Hospital trials

Trials by the same sponsor.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02697838 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
Last refreshed: 17 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02697838.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing